LB Pharmaceuticals Inc LBRX

US Pharmaceuticals

$40.08 ▼ -2.00% ($-0.82)

🔥 High Short Interest 🗓️ Earnings Next Week

Open $40.39

Prev Close $40.90

Day Range $38.98 – $40.67

52W Range $13.36 – $41.33

Market Cap $1.15B

Beta 1.22

EPS (TTM) $-1.72

📋 Company Profile

Industry	Pharmaceuticals
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2025-09-11
Shares Out.	28,680,000
Website	lbpharma.us/ ↗
Phone	19174506581
Employees	27
Net Income	-$19.1M
Total Assets	$393.5M
Total Liabilities	$14.8M
Equity	$378.7M

About LB Pharmaceuticals Inc

LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.

LB Pharmaceuticals Inc is a publicly traded company under the ticker symbol LBRX on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.